Presentation: HAND is Common and Important in Patients on ART, Igor Grant, MD (PDF)

Drs. Igor Grant and Scott Letendre presented at the third North European Workshop on HIV–infection in the central nervous system (HANSA 2013) that took place in Berlin, Germany, 26-27 April 2013.  The aim of HANSA 2013 is to assemble clinicians and researchers together to advance knowledge of ongoing HIV central nervous system (CNS) research. The conference covered basic issues and controversies.

Both HNRP investigators participated in Session 3 - Controversies.  Dr. Letendre supports the position that CNS penetration is important to consider when choosing an anti-retroviral therapy (ART) regimen (vs. CNS penetration not being of primary concern) and Dr. Grant (PDF) argues that HIV associated neurocognitive decline (HAND) is common and important to consider in patients on ART (vs. HAND being negligible in patients on ART).

Related publications:

Letendre S.  (2011). Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Topics in Antiviral Medicine, 19(4), 137-42. PMID: 22156215

Letendre SL, Ellis RJ, Ances BM, McCutchan JA.  (2010). Neurologic complications of HIV disease and their treatment. Topics in HIV Medicine : a Publication of The International AIDS Society, USA, 18(2), 45-55. PMID: 20516524

The Mind Exchange Working Group.  (2013). Assessment, diagnosis and treatment of Human Immunodeficiency Virus (HIV)-associated neurocognitive disorders (HAND): A consensus report of the Mind Exchange Program. Clinical Infectious Diseases, 56(7), 1004-1017. PMID: 23175555

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt M, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, the CHARTER Group, and the HNRC Group.  (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. Journal of NeuroVirology, 17(1), 3-16. PMID: 21174240  PMCID: PMC3032197

Heaton RK, Clifford DB, Franklin Jr DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, and the CHARTER Group.  (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology, 75(23), 2087-2096. PMID: 21135382  PMCID: PMC2995535